Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease.
about
Pharmacotherapy for end-stage coronary artery disease.VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trialPlacebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trialTargeting vascular endothelial growth factor in angina therapy.Angiogenesis: bench to bedside, have we learned anything?Myocardial therapeutic angiogenesis: a review of the state of development and future obstaclesExercise-induced expression of VEGF and salvation of myocardium in the early stage of myocardial infarction.Human studies of angiogenic gene therapy.Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.Angiogenic gene therapy for refractory angina.Advancements in pharmacotherapy for angina.A meta-analysis of temporal changes of response in the placebo arm of surgical randomized controlled trials: an update.High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial.Long-Term and Sustained Therapeutic Results of a Specific Promonocyte Cell Formulation in Refractory Angina: ReACT(®) (Refractory Angina Cell Therapy) Clinical Update and Cost-Effective Analysis.Randomized trials are also essential for device therapy.
P2860
Q33610142-0702269B-4446-4923-9457-99BF617A2326Q33713721-CA3DB4ED-3BB0-47F0-A5C4-74E55280820EQ34487591-ACFE8D07-7A66-4A5F-953B-4CD96033BA53Q35596336-4983C5D2-CB38-407F-934C-0C05ED3B55A3Q36379360-B231C946-4872-4EA2-9AF5-C95D589FBC20Q36409434-EFA49113-138B-4C75-82A8-0F47A23F1CA1Q36820684-C21656DE-9FA8-4C44-83D7-EAAA5D87EA19Q37100213-E4E261AA-D6A6-4160-BE8C-566160EED035Q37406656-A081C1EE-D748-4689-B4FE-CE986A7B0339Q38081027-C00997AF-87CF-4C6D-BAC8-6FFCE3DD38F2Q38637597-5C2A9512-FF5F-4AC6-8BC9-48FDA1886885Q39164200-BAC4F244-6E94-44F5-910B-4F3685CAD7E2Q39431104-F38F25C6-C73B-459E-B5FC-29B40CA3B42AQ45880368-3BA53412-B1B0-4702-A504-FCB1EFFE8277Q48076745-668FD437-5723-409C-B498-49D5F1741CD0Q51143431-02FB5108-C321-4D29-9669-A3336347C0F1
P2860
Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Longevity of the placebo effec ...... s with coronary heart disease.
@ast
Longevity of the placebo effec ...... s with coronary heart disease.
@en
type
label
Longevity of the placebo effec ...... s with coronary heart disease.
@ast
Longevity of the placebo effec ...... s with coronary heart disease.
@en
prefLabel
Longevity of the placebo effec ...... s with coronary heart disease.
@ast
Longevity of the placebo effec ...... s with coronary heart disease.
@en
P2093
P1476
Longevity of the placebo effec ...... s with coronary heart disease.
@en
P2093
Arjuna Mannam
Ernesto V Gervino
Frank W Sellke
Jamal S Rana
Laurel Donnell-Fink
Roger J Laham
P304
P356
10.1016/J.AMJCARD.2005.02.013
P407
P577
2005-06-01T00:00:00Z